AnaptysBio CEO to speak at H.C. Wainwright Royalty Company Virtual Conference on May 6, 2026

AnaptysBio announced that its CEO, Daniel Faga, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, 2026. The company focuses on managing financial collaborations for its drugs Jemperli with GSK and imsidolimab with Vanda, aiming to protect and return royalty value to shareholders. This event provides an opportunity for investors to hear directly from the CEO about the company's strategies and outlook. The fireside chat is scheduled for 1:30pm ET and interested parties can register online.